Pregnancy in paroxysmal nocturnal hemoglobinuria: from survival to life

Cover Page

Cite item

Full Text

Abstract

Background. Pregnancy in paroxysmal nocturnal hemoglobinuria (PNH) patients has historically been a high-risk situation. The combination of chronic complement-mediated hemolysis caused by the disease and physiological activation of the complement system during pregnancy, significantly worsened the prognosis for the life. For a long time, there were no effective methods for the PNH treatment, and pregnancy in patients seemed to be extremely risky, as it significantly increased the risk of life-threatening complications. The advent of targeted therapy with eculizumab turned the prognosis of this disease upside down: patients began not only to survive, but also to live comparable to healthy people. A comparative analysis of the course and outcomes of pregnancy in patients with PNH treated with eculizumab and in patients without targeted therapy was carried out.

Aim. The study was to evaluate the course and outcomes of pregnancy in patients with PNH, depending on the therapeutic approach.

Materials and methods. We analyzed data from 57 pregnancies in 49 women (31 used eculizumab, 26 with supportive care only) observed at the Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology or with remote consultation (23 clinics from 19 cities of Russia).

Results. The high probability of pregnancy complications and its adverse outcomes outside of targeted therapy indicates the vital need for its use: all observations were accompanied by complications of varying severity. The course of pregnancy with the eculizumab is generally more favorable: an apparently higher rate of live births and a lower likelihood of complications are registered. Without increasing the incidence of complications, eculizumab significantly improves pregnancy outcomes for both mother and fetus, and does not adversely affect the health of newborns.

Conclusion. Thus, eculizumab allows not only to increase the survival rate of patients with PNH, but also to comprehensively improve their quality of life, including the possibility of safe childbirth.

About the authors

Maria A. Vinogradova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: mary-grape@yandex.ru
ORCID iD: 0000-0001-9827-1922

канд. мед. наук, зав. отд-нием репродуктивной гематологии и клинической гемостазиологии

Russian Federation, Moscow

Alexander D. Kulagin

Pavlov First Saint Petersburg State Medical University

Email: mary-grape@yandex.ru
ORCID iD: 0000-0002-9589-4136

д-р мед. наук, проф., и. о. зав. каф. гематологи, трансфузиологии, трансплантологии с курсом детской онкологии фак-та послевузовского образования им. проф. Б.В. Афанасьева, дир. клиники «Научно-исследовательский институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой»

Russian Federation, Saint Petersburg

Roman G. Shmakov

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: mary-grape@yandex.ru
ORCID iD: 0000-0002-2206-1002

д-р мед. наук, проф., дир. Института акушерства

Russian Federation, Moscow

References

  1. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253-8. doi: 10.1056/NEJM199511093331904
  2. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis. 2000;30(3):103-17. doi: 10.1159/000022532
  3. Hillmen P, Young NS, Schubert J. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-43. doi: 10.1056/NEJMoa061648
  4. Derzsy Z, Prohászka Z, Rigó J Jr, et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47(7-8):1500-16. doi: 10.1016/j.molimm.2010.01.021
  5. Girardi G. Complement activation, a threat to pregnancy. Semin Immunopathol. 2018;40(1):103-11. doi: 10.1007/s00281-017-0645-x
  6. Luzzato L. Control of hemolysis in patients with PNH. Blood. 2021;138(20):1908-10. doi: 10.1182/blood.2021013169
  7. Brodsky RA. How I treat Paroxysmal Nocturnal Hemoglobinuria. Blood. 2021;137(10):1304-9. doi: 10.1182/blood.2019003812
  8. Vinogradova MA, Kulagin AD, Shmakov RG, et al. The Pregnancy Course and Outcomes during Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria. Blood. 2016;128(22):2397. doi: 10.1182/blood.V128.22.2397.2397
  9. de Guibert S, Peffault de Latour R, Varoqueaux N, et al. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica. 2011;96(9):1276-83. doi: 10.3324/haematol.2010.037531
  10. Miyasaka N, Miura O, Kawaguchi T, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol. 2016;103:703-12. doi: 10.1007/s12185-016-1946-x
  11. Al-Dosari YM, Al-Zahrani H, Al-Mohareb F, Hashmi S. Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Case Series with Review of the Literature. Saudi J Med Med Sci. 2021;9(2):178-89. doi: 10.4103/sjmms.sjmms_4_20
  12. Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032-9. doi: 10.1056/NEJMoa1502950
  13. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553-9. doi: 10.1002/ajh.21757
  14. Patel A, Unnikrishnan A, Murphy M, et al. Paroxysmal Nocturnal Hemoglobinuria in Pregnancy: A Dilemma in Treatment and Thromboprophylaxis. Case Rep Hematol. 2017;2017:7289126. doi: 10.1155/2017/7289126
  15. Alashkar F, Saner FH, Vance C, et al. Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation. Front Med (Lausanne). 2020;7:543372. doi: 10.3389/fmed.2020.543372
  16. Птушкин В.В., Кулагин А.Д., Лукина Е.А., и др. Результаты открытого многоцентрового клинического исследования Ib фазы по оценке безопасности, фармакокинетики и фармакодинамики первого биоаналога экулизумаба у нелеченых пациентов с пароксизмальной ночной гемоглобинурией в фазе индукции терапии. Терапевтический архив. 2020;92(7):77-84 [Ptushkin VV, Kulagin AD, Lukina EA, et al. Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(7):77-84 (in Russian)]. doi: 10.26442/00403660.2020.07.000818
  17. Kulagin AD, Ptushkin VV, Lukina EA, et al. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol. 2021;100(11):2689-98. doi: 10.1007/s00277-021-04624-7
  18. Kulagin A, Ptushkin V, Lukina E, et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(Suppl. 1):3748. doi: 10.1182/blood-2019-125693

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies